Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study

• Váldodahkkit: Zhuoling Zheng (Dahkki), Yihong Zhao (Dahkki), Jingwen Xie (Dahkki), Min Gao (Dahkki), Yiting Wang (Dahkki), Xiaoyan Li (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2024-10-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

IntroductionBevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is widely used as a first-line treatment for metastatic colorectal cancer (mCRC), with hypertension being a common adverse effect. However, there is limited data on the predisposing factors contributing to bevacizumab-in...